Cellectis Ownership
| CLLS Stock | USD 1.82 0.11 5.70% |
Shares in Circulation | First Issued 2011-12-31 | Previous Quarter 100.1 M | Current Value 100.2 M | Avarage Shares Outstanding 43.5 M | Quarterly Volatility 21.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Cellectis | Build AI portfolio with Cellectis Stock |
Cellectis Stock Ownership Analysis
About 21.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.57. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cellectis SA recorded a loss per share of 0.67. The entity had not issued any dividends in recent years. Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Cellectis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 294 people. For more info on Cellectis SA please contact Andre Choulika at 33 1 81 69 16 00 or go to https://www.cellectis.com.Besides selling stocks to institutional investors, Cellectis also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Cellectis' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Cellectis' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Cellectis Quarterly Liabilities And Stockholders Equity |
|
Roughly 4.0% of Cellectis SA are currently held by insiders. Unlike Cellectis' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Cellectis' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Cellectis' insider trades
Cellectis Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cellectis is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cellectis SA backward and forwards among themselves. Cellectis' institutional investor refers to the entity that pools money to purchase Cellectis' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | First Affirmative Financial Network | 2025-03-31 | 25.9 K | Old Mission Capital Llc. | 2025-03-31 | 25.3 K | Wells Fargo & Co | 2025-03-31 | 22.8 K | Baird Financial Group, Inc. | 2025-03-31 | 15.1 K | Cubist Systematic Strategies, Llc | 2025-03-31 | 10.9 K | Geode Capital Management, Llc | 2025-03-31 | 10.8 K | Federation Des Caisses Desjardins Du Quebec | 2025-03-31 | 10.7 K | Harbour Investments, Inc. | 2025-03-31 | 4.5 K | Rhumbline Advisers | 2025-03-31 | 2.1 K | Ubs Asset Mgmt Americas Inc | 2025-03-31 | 4.7 M | Long Focus Capital Management, Llc | 2025-03-31 | 4.7 M |
Cellectis Outstanding Bonds
Cellectis issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cellectis SA uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cellectis bonds can be classified according to their maturity, which is the date when Cellectis SA has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| CELARA 3875 02 NOV 27 Corp BondUS151191BB89 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| US15118JAA34 Corp BondUS15118JAA34 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.